MyLifeIQ

What MyLifeIQ does

MyLifeIQ is a privately held, for-profit healthcare company headquartered in Dallas, Texas, that positions itself as an epigenetics platform focused on transitioning healthcare delivery toward precision medicine. The firm is at an early commercial stage, with a small team of 1-10 employees and a single public web presence at mylifeiq.com. No specific product offerings, service descriptions, pricing model, or customer base are documented in the input material beyond the firmographic profile and the company's own high-level positioning statement.

The company's focus on epigenetics implies that its intended value proposition sits at the intersection of molecular biomarker analysis (such as DNA methylation patterns) and individualized health insight delivery. The precision-medicine framing suggests an ambition to translate biological data into actionable, patient- or provider-facing outputs, though the input does not specify whether the offering is direct-to-consumer, clinical decision support, employer-sponsored, or research-oriented. No underlying technology stack, platform architecture, data assets, or scientific methodology is described in the available data.

Beyond the basic firmographic record, no funding history, strategic partnerships, named customers, revenue figures, awards, regulatory milestones, or operational metrics are documented for MyLifeIQ in the provided input. The breadth of detail available is materially below what would normally support a full investment thesis, and any analytical conclusions should be treated as preliminary pending further disclosure from the company or primary-source verification.

Name

MyLifeIQ

Legal name

Recuro Health

Website

https://mylifeiq.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

MyLifeIQ is a privately held, early-stage Dallas-based company positioning itself as an epigenetics platform focused on transitioning healthcare toward precision medicine through individualized, biomarker-driven health insights.

Ownership category

akta.pro rank

Product category

Epigenetics Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169)

akta.pro primary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

akta.pro secondary industries

Epigenomics & Chromatin Profiling Services (HLAGANAF), Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)

Keywords

• Epigenetics platform
• Precision medicine
• Personalized healthcare
• Biological biomarkers
• Health analytics

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Software

Revenue model

1. Virtual Care Services Subscription: Provides virtual primary care, urgent care, and behavioral health services to members. Services are offered to employers, health plans, and directly to consumers through employer-sponsored benefits.
2. Integrated Benefits Solutions: Offers integrated virtual care solutions including health advocacy, prescription benefits, wellness programs, and MSK therapy as part of comprehensive employer health benefits packages.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Core offering

MyLifeIQ operates an epigenetics platform designed to transition healthcare toward precision medicine by analyzing epigenetic markers to deliver personalized health insights and interventions. The company focuses on applying epigenetic science to enable individualized healthcare decisions rather than generalized, one-size-fits-all treatment protocols.

Product overview

Recuro Health operates as a platform-plus-modules architecture offering integrated virtual healthcare solutions. The core platform includes three primary products: Recuro Primary Care (coordinated care through dedicated doctors), Recuro Behavioral Health (mental health services across therapy and psychiatry), and Recuro Urgent Care (24/7 immediate care). These are supplemented by add-on modules including On-Demand Counseling, Health Advocacy, Pediatric Behavioral Health (acquired via Wellvia), Prescription Benefit, Wellness Program, and Virtual MSK Therapy. The platform integrates genomic testing, at-home labs, and health risk assessments into consultations, enabling proactive and preventive care.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 3.5x-6x ROI for clients using integration and utilization tactics
• +4 more outcomes

Named customers5 records

Segments5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• WellviacoreStrategic or Co-development PartnerRecuro Health acquired Wellvia, a premier virtual health provider that remotely connects patients to board-certified physicians and behavioral health specialists. The acquisition significantly expanded Recuro's digital health capabilities and provider network.

Scale indicators7 records

Expansion highlights2 records

Emerging players

• 23andMe: 23andMe is a consumer-focused genetic testing platform that has begun expanding into epigenetic-style health insights; comparable as a DTC health data platform but adjacent on the epigenetic axis rather than direct.
• Personal Genome Diagnostics (Labcorp): PGDx provides genomic and emerging epigenomic biomarker testing services for clinical and biopharma use cases, overlapping with MyLifeIQ's translational interpretation niche.
• Impute.me / SelfDecode: SelfDecode offers consumer-facing genetic and epigenetic interpretation tools focused on personalized health and lifestyle — comparable as smaller, software-led, epigenetics-focused precision medicine platform.

Direct peers

• SomaLogic (Standard BioTools): SomaLogic operates a large-scale proteomics platform and is increasingly extending into multi-omics interpretation for clinical research, a directly comparable 'omic-to-precision-medicine' software/services model.
• TruDiagnostic: TruDiagnostic is a commercial epigenetic (DNA methylation) testing and biological-age platform that converts epigenomic data into actionable health insights — the most direct commercial analogue to MyLifeIQ.
• Tempus Labs: Tempus operates a data-enabled precision medicine platform combining multi-omics (including methylation/epigenomics) sequencing with clinical decision support, closely paralleling an epigenetics-to-precision-medicine platform.
• Color Health: Color provides population-scale genetic and epigenetic testing combined with a clinical platform for results interpretation and provider integration, comparable to an epigenetics software/healthcare bridge.
• Human Longevity Inc. Human Longevity combines whole-genome and other omics data with clinical interpretation to drive precision health — a directly comparable multi-omics interpretation platform.

Broad incumbents

• Illumina: Illumina controls the dominant DNA sequencing platform that underpins virtually all epigenetic assays; relevant as a broad incumbent whose chemistry and instruments shape the upstream data MyLifeIQ's platform would consume.
• Foundation Medicine (Roche): Foundation Medicine provides comprehensive genomic profiling and interpretation for oncology — a broad incumbent in precision medicine interpretation with adjacent (though largely genomic, not epigenetic) technology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks6 records

Key highlights5 records

Customer concentration

• Xtwitter.com/recuro_health
• Facebookfacebook.com/recurohealthcare
• LinkedInlinkedin.com/company/mylifeiq

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MyLifeIQ